The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
 
Rachel Occhiogrosso Abelman
No Relationships to Disclose
 
Laura Spring
Consulting or Advisory Role - AstraZeneca; Daiichi Pharma; G1 Therapeutics; Lilly; Novartis; Precede Bio; Seagen
Research Funding - Genentech/Roche; Gilead Sciences; Lilly; Merck (Inst)
 
Andrzej Niemierko
No Relationships to Disclose
 
Elizabeth Abraham
No Relationships to Disclose
 
Mary McNeice
No Relationships to Disclose
 
Jennifer Goff
No Relationships to Disclose
 
Amanda Valenti
No Relationships to Disclose
 
Seth Andrew Wander
Consulting or Advisory Role - AstraZeneca; Biovica; Foundation Medicine; Hologic; Lilly; Novartis; Pfizer; Puma Biotechnology; Veracyte
Speakers' Bureau - 2nd.MD; Guardant Health; Lilly; Novartis
Research Funding - Genentech; Lilly; Nuvation Bio; Pfizer; Regor Therapeutics; Sermonix Pharmaceuticals
 
Steven J. Isakoff
Employment - Merus (I)
Stock and Other Ownership Interests - Merus NV (I)
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Merck (Inst); OncoPep (Inst)
 
Beverly Moy
Consulting or Advisory Role - HRA Pharma
 
Dejan Juric
Stock and Other Ownership Interests - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Consulting or Advisory Role - AstraZeneca; Eisai; Genentech; Lilly; MapKure; Novartis; Pfizer; PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Eisai (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Scorpion Therapeutics; Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)
 
Neelima Vidula
Consulting or Advisory Role - AADi; Gilead Sciences; OncoSec; Stemline Therapeutics; Tersera
Research Funding - DAEHWA Pharmaceutical (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst)
 
Adrienne Gropper Waks
Consulting or Advisory Role - AstraZeneca
Research Funding - Genentech (Inst); Gilead Sciences (Inst); MacroGenics (Inst); Merck (Inst)
 
Heather Anne Parsons
Honoraria - Guardant Health
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo/UCB Japan; Natera; SAGA Diagnostics; Sermonix Pharmaceuticals
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - NeoGenomics Laboratories; SAGA Diagnostics
 
Leif W. Ellisen
Consulting or Advisory Role - Gilead Sciences; KisoJi Biotechnology; mersana
 
Sara M. Tolaney
Consulting or Advisory Role - AADi; ARC Therapeutics; Artios Biopharmaceuticals; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; CytomX Therapeutics; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Infinity Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Menarini Group; Merck; Natera; Novartis; OncXerna Therapeutics; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Sanofi
 
Aditya Bardia
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)